Protocol Ledger

NCT06868485 · Phase II · RECRUITING

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT06868485 sponsored by Wayshine Biopharm in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-08-18 Enrollment: 40 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06868485
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06868485
Protocol FieldVerified Registry Value
NCT IdentifierNCT06868485
Consolidated Lead SponsorWayshine Biopharm
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment40 participants (ESTIMATED)
Registered Start Date2025-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06868485
Hospital Research SiteLocationSite Profile
Cleveland Clinic FloridaWeston, FLOpen Hospital Dossier ->
Karmanos Cancer InstituteDetroit, MIOpen Hospital Dossier ->
Cleveland ClinicCleveland, OHOpen Hospital Dossier ->
UPMC Hillman Cancer CenterPittsburgh, PAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI